Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3075 Telotristat Makes Significant Difference on Symptoms and Serotonin Levels in a Population with Widespread GI-NET and Severe Carcinoid Syndrome

Introduction: In spite of new treatments like PRRT or everolimus there is a clinical need for systemic therapies that complement SSAs (somatostatin analogs) and antidiarrheal agents in the treatment of carcinoid syndrome, a late stage problem in s-i-NET. Telotristat is a promising addition to our therapeutic arsenal.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Linder Ekberg K,

Keywords: telotristat, carcinoid syndrome, metastasized GI-NET,

#2731 177Lu-DOTATATE Plus 166Ho-Radioembolization in Patients with Neuroendocrine Tumours; A Single Center, Prospective, Interventional, Non-Comparative, Open Label, Phase II Study (HEPAR PLuS Study)

Introduction: The liver is the most commonly affected organ in metastatic neuroendocrine disease and is the most incriminating factor for patient survival. Additional treatment of liver disease with radioembolization may improve outcome in NET patients with bulky residual liver disease after PRRT.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Braat A

Authors: Braat A, Rutger B, Van Rooij R, Braat M, Wessels F,

Keywords: NET, PRRT, SIRT, Radioembolization, Ho-166, Neuroendocrine tumor,

#2252 Safety and Efficacy of TAE and SIRT in NET Patients

Introduction: Transarterial embolization (TAE) and Selective Internal Radiation Therapy (SIRT) are used for treating patients with liver metastases of a neuroendocrine tumour (NET). However, the safety and effectiveness of TAE and SIRT have scarcely been compared.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Van Veenendaal L, Braat A, Meier M, Samsom K, Verbeek W,

Keywords: neuroendocrine tumor, liver metastases, therapy, radioembolization, transarterial embolization, safety, efficacy,

#1683 International Multicenter Retrospective Study on the Efficacy and Toxicity of Radioembolization in Neuroendocrine Tumours with Yttrium-90 Resin Microspheres

Introduction: Radioembolization (RE) is applied worldwide in patients with liver-dominant metastatic neuroendocrine tumours (mNET). Current literature is of poor quality and based on small heterogeneous populations

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Braat A

Authors: Braat A, Mahvash A, Stothers C, Deroose C, Frilling A,

Keywords: neuroendocrine tumors, radioembolization, sirt,

#1293 The Role of Hepatic Intra-arterial Therapies in Metastatic Neuroendocrine Tumours (NETs): A Specialist Center Experience.

Introduction: Liver metastases are relatively common in patients with NETs, having a negative impact on prognosis. The options for selective liver metastases therapy are limited to catheter guided procedures: TACE, TAE or SIRT. Data regarding the effectiveness & safety of these procedures in different types of NETs is limited.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Grozinsky-Glasberg S, Klimov A, Salmon A, Besiso H, Maimon O,

Keywords: hepatic chemoembolization, SIRT, NETs, MTC,